According to species-independent clinical breakpoints provided by the European Committee on Antimicrobial Susceptibility Testing (EUCAST, 2014), our isolate was susceptible to aztreonam
, ceftazidime, cefotaxime, piperacillin-tazobactam, ticarcillin-clavulanate, and carbapenems, but resistant to all aminoglycosides tested and ciprofloxacin.
So we analysed carbapenems, ceftazidime and aztreonam
as phenotypical indicator substrates of [beta]-lactamases (2) in the strains of both origin.
pneumoniae presentaron resistencia a las cefalosporinas de tercera generacion y al monobactamico aztreonam
, las concentraciones minimas inhibitorias detectadas fueron de 32 a >256 [micron]g/mL para ceftazidima y aztreonam
y de 4 a >256 [micron]g/mL para cefotaxima y ceftriaxona (Tabla I).
In all strains with ES[beta]Ls, the MICs for one or more of the extended-spectrum cephalosporins or aztreonam
should decrease in the presence of clavulanic acid as determined in phenotypic confirmatory testing.
Most Salmonella isolates, irrespective of species, were sensitive to amikacin, aztreonam
, ceftriaxone, and nalidixic acid.
Out of 10 Acinetobacter baumannii isolated in this study, 10 (100%) were sensitive to Polymyxin-B, 8 (80%) were sensitive to Amikacin followed by 7 (70%) were sensitive to Imipenem, 6 (60%) to Meropenem, Aztreonam
, Ciprofloxacin and Gentamicin.
Antibiotic susceptibility to newer antibiotics ([micro]g) like imipenem--cilastin (10/10), piperacillin (100), cefepime (30), imipenem (10 [micro]g), aztreonam
(30 [micro]g) and beta-lactam beta lactamase inhibitor combinations such as amoxicillin-clavulanic acid (30/10), ampicillin-sulbactam (10/10), piperacillin-tazobactam (100/10) and ceftazidime-clavulanic acid (30/10) was performed by the NCCLS method.
Ceftazidime and aztreonam
resistance in Providencia stuartii: characterization of a natural TEM-derived extended spectrum [beta]-lactamase, TEM-60.
The antibiotic discs of amikacin (30 g) aztreonam
(30 g) cefepime (30g) cefixime (5 g) cefotaxime (30 g) cefoxitin (30 g) cefpodoxime (30 g) ceftazidime (30 g) cefuroxime (30 g)
NDM-1], which confers resistance to all beta-lactam agents except aztreonam
(a monobactam antimicrobial) (1); all three isolates were aztreonam
resistant, presumably by a different mechanism.
Studies of an inhaled formulation of the monobactam antibiotic aztreonam
in patients with cystic fibrosis show that it is a safe and effective treatment for Pseudomonas aeruginosa lung infections in this population, a federal advisory panel concluded in a 15-2 vote.
had provided substantial evidence that inhaled aztreonam
, administered at a dose of 75 mg three times a day for 28 days, was safe and effective for the proposed indication: the improvement of respiratory symptoms and pulmonary function in patients who have cystic fibrosis (CF) with P.